FDA Orange Book · active-ingredient family
Ceftazidime
Ceftazidime: 3 brands, 11 generics; first approved Jul 19, 1985; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 11 ANDA applications approved.
Brands (NDA)
3
Generics (ANDA)
11
Listed patents
0
Presentations
35
Brand (NDA) products
Originator applications
- B BRAUNNDA 05082320112 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 1GM BASE INJECTABLE INJECTION Discontinued — EQ 2GM BASE INJECTABLE INJECTION Discontinued — - FORTAZRLDPAI HOLDINGS PHARMNDA 05057819854 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Discontinued — 1GM/VIAL INJECTABLE INJECTION Discontinued — 2GM/VIAL INJECTABLE INJECTION Discontinued — 6GM/VIAL INJECTABLE INJECTION Discontinued — - GLAXOSMITHKLINENDA 05064619904 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Discontinued — 1GM/VIAL INJECTABLE INJECTION Discontinued — 2GM/VIAL INJECTABLE INJECTION Discontinued — 10GM/VIAL INJECTABLE INJECTION Discontinued —
Generic (ANDA) products (11)
Abbreviated applications
- CEFTAZIDIMEAUROBINDO PHARMA LTDANDA 06548120103 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Discontinued — 1GM/VIAL INJECTABLE INJECTION Discontinued — 2GM/VIAL INJECTABLE INJECTION Discontinued — - CEFTAZIDIMEAUROBINDO PHARMA LTDANDA 0654822010
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/VIAL INJECTABLE INJECTION Discontinued — - CEFTAZIDIMEWOCKHARDTANDA 0651962008
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1GM/VIAL INJECTABLE INJECTION Discontinued — - GLAXOSMITHKLINEANDA 06332219952 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1GM/VIAL INJECTABLE INJECTION Discontinued — 2GM/VIAL INJECTABLE INJECTION Discontinued — - HOSPIRAANDA 06403219932 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP - GLAXOSMITHKLINEANDA 06400619922 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1GM/VIAL INJECTABLE INJECTION Discontinued — 2GM/VIAL INJECTABLE INJECTION Discontinued — - GLAXOSMITHKLINEANDA 06400819922 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 6GM/VIAL INJECTABLE INJECTION Discontinued — 10GM/VIAL INJECTABLE INJECTION Discontinued — - LILLYANDA 06273919862 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1GM/VIAL INJECTABLE INJECTION Discontinued — 2GM/VIAL INJECTABLE INJECTION Discontinued — - HOSPIRAANDA 06266219864 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Discontinued — 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP 6GM/VIAL INJECTABLE INJECTION Rx AP - CEFTAZIDIMERSACS DOBFARANDA 06264019854 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/VIAL INJECTABLE INJECTION Discontinued — 1GM/VIAL INJECTABLE INJECTION Rx AP 2GM/VIAL INJECTABLE INJECTION Rx AP 6GM/VIAL INJECTABLE INJECTION Rx AP - LILLYANDA 06265519852 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1GM/VIAL INJECTABLE INJECTION Discontinued — 2GM/VIAL INJECTABLE INJECTION Discontinued —
Listed patents
Orange Book patent file
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
FDA approval span
First approval
41 yr 8 mo ago
Most recent approval
15 yr 5 mo ago
Approvals span 1985–2011 across 14 FDA applications.
Brand (NDA) 321%
Generic (ANDA) 1179%
Ceftazidime: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
